• Understand challenges round storage and shipping to ensure drug quality
• Build reporting networks that meet regulation requirements and ensure patient safety
• Protect patient data safety with 3rd party partners including couriers

• Learn how to identify and plan the initial studies for DCT approaches to scale
• Understand how to evaluate country-specific regulatory requirements and feature specific limitations
• Assess DCT providers for optimal capabilities related to integrations, technical helpdesk, device provisioning and multi-lingual support availability

• Understand the developments in protocol design practices across 2020 and the pandemic
• Assess the impact of decentralization and other approaches on clinical trial performance and efficiency
• Discuss solutions and strategies to optimize protocol designs including patient advisory board input and organization-wide data governance and coordination mechanisms

• Make your trials more accessible by using patient-generated health data to better identify target trial populations and facilitate participation from otherwise unrepresented patient populations
• Understand the biases in patient-generated data and discover how to overcome difficulties in analysis and data storage

• Understand how to break down data silos across clinical trial and real world data to ensure greater understanding of drug efficacy and post-launch patient outcomes.
• Employ proper patient consent, data linking, tokenization and patient identification technologies to fix the broken feedback loop and enable a wide variety of use cases, including patient safety monitoring, trial design and long-term therapeutic efficacy beyond the duration of clinical trials
• Discover the rewards and risks associated with data linkage that facilitates merging information from clinical trial and real world data

• Discover a modern stacked approach to enrollment forecasting that leverages historical data as well as within-time-series predictive modeling
• Understand the Impacts of the pandemic on enrollment and screening across Therapy Area and region
• Discuss future applications for these capabilities across other clinical operations use cases"

• Understand the key pre-trial measures needed to enable interoperability between digital tools, sites and data capture measures
• Utilise big data, AI and ML to prioritise data outputs, identify novel endpoints and build endpoint flexibility into trial design
• Discover the tools and projects currently driving the future of agile, data driven trial design

• Discover details on the new Diversity Guidance, releasing 2021
• Gain advice on implementation issues specific to the US including alternative submissions
• Discover the possibilities for RWD integration within existing models and discuss upcoming updates

• Discover how patient-centric priorities such as patient data return and early co-creation are driving innovation in DCT design
• Connect the disconnected: Novel digital channels that drive novel patient group collaboration and raise awareness of trial opportunities in under-represented patient populations
• Employ digital tools to train and implement best practices for diverse recruitment
• Discover how to overcome patient digital fatigue and encourage trial retention

• Discover how diversity is coming to prominence in the age of the democratization of clinical trials
• Learn how technology is transforming the future of clinical trials and facilitating patient support programs for commercially approved products
• Understand how Otsuka are forming clinical trial strategy based on recent industry guidelines

• Treatments: Discover strategies to identify, enroll and equip COVID-19 positive (+) patients to participate remotely from their home, including novel approaches to reach patients with critical supplies and IMP
• Vaccines: Learn how to reduce on-site visits for COVID-19 negative (-) patients through the utilization of mobile sites to protect vulnerable patient populations from potential exposure
• Long COVID: Understand which post-pandemic research modalities should be considered as new variants emerge and long-term follow-up is needed for patients working towards recovery

• See the progress of clinical trial modernization since COVID-19, key remaining challenges and how to drive sustainable change in the future
• Learn how TransCelerate’s Modernizing Clinical Trial Conduct Initiative has led to improved patient centricity through reduced clinical trial conduct burdens

• Achieve sustainable progress towards a more patient-centric reality as health care research becomes increasingly decentralized and digitized
• Learn which steps you can take to center digital transformation on the patient experience and deliver meaningful value to the individual, their family, caregivers, and broader society

• Learn how a connected ecosystem model across the clinical development and pharmaceutical product lifecycle can drive efficiency and ensure a patient centric strategy across the clinical and commercial continuum
• Learn how to utilize an interoperable end to end digital health platform that utilizes real time patient data in clinical trial design and improves outcomes
• How to create an intuitive user experience within virtual trials including applying AI and ML

• HOLD

• How Sanofi’s ground-breaking Parkinson’s digital biomarker programme incorporated patient and clinician perspectives, in detail and at scale
• Discover how to engage regulators early, often, and globally when building a ‘minimum viable product’
• Put patient centricity hypotheses to the test in the lab and at home

• Understand the challenges, ideas and practical solutions for protecting your clients, patients and business strategy amidst the escalating cyber threat landscape.
• Develop a data and technology strategy to maximize business the opportunities presented by accelerated digitalisation and online collaboration.
• Questions you should be asking the business - so that you can collectively protect your crown jewels from threat actors.

• How to combine patient insights and behavioral sciences with data and analytics, to personalize the connection with patients in clinical trials.
• How can behavioral science be implemented across the clinical trial lifecycle.
• How to apply patient activation in clinical trials and predict patient’s willingness to participate.

• Identify your primary objectives of implementing PE experience in post-pandemic early phase R&D
• Build partnerships by selecting the most appropriate approaches to engaging with your patients during early phase R&D
• Develop condition profiles using PE experience in early phase R&D
• Introduce PE experience to R&D design of methodology & TVP/TPP in early phase R&D

• Discuss the multiple strategic and operational dimensions involved in Decentralized Clinical Trials (DCTs)
• Understand the concept and principles of Clinical Research as a Care Option (CRAACO)
• Explore synergies that exist between Decentralized Clinical Trials (DCTs) and CRAACO
• Adopt and adapt fit-for-purpose technology for DCTs applying CRAACO
• Appraise enhancing patient experience and including diversity in DCTs applying CRAACO compared to traditional trials

Due to Covid-19, life sciences organisations are pressured to accelerate collaboration across their clinical researchers, clinicians, sponsors, and external alliances like CROs and Labs. Traditional in-person clinical site workflows, like document verifications or clinical site monitoring digital are challenged without an easy way to share and collaborate on clinical site documents, analyse it, and then drive it through the value chain quickly.

Join Manu Vohra, Managing Director, Life Sciences, Katherine Davidson, Large Enterprise Account Executive, Marco Rohr, Large Enterprise Account Executive, Jan Husemeier, Large Enterprise Account Executive, Box to discuss:

• Why in-person or paper-based clinical workflows like, reporting, auditing, monitoring or verification are no longer viable
• Clinical data is stuck in silos because CROs, Hospitals, and Clinics have many different technologies in place
• Getting clinicians trained on multiple systems in order to access trial info is time consuming and slows down clinical operations
• Purpose built solutions are incredibly costly and do not allow custom integrations
• Lack of control and visibility into how data is being shared creates data leak risk
• Compliance violations are costly and can hurt brand reputation especially when patient data (PII) is concerned

Accelerate clinical R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Designed with content at the center, Box is the content cloud: one secure platform for managing your clinical and patient records in the cloud.

Discuss the challenges, ideas and practical solutions for protecting the Life Sciences sector amidst the escalating cyber threat landscape. 

They will kick off the discussion and share their experiences and perspectives on keeping data safe.

Join Abel Archundia, MD Life Sciences, Istari, & Advisor to BlueVoyant, formerly the Global Pharma CIO and Digital Transformation at Bayer, Robert Hannigan CMG a cybersecurity specialist and International Chairman, BlueVoyant and Dr. Amy Williams, Director of Proactive Services, BlueVoyant as they explore the following questions:

• Developing a data and technology strategy to maximize business the opportunities presented by accelerated digitalisation and online collaboration.
• Third-party and supply chain cyber risk has the attention of the Board - the inherent risks that COVID-19 presented has accelerated this visibility. What are the lessons learnt from other industry sectors? 
• Questions you should be asking the business - so that you can collectively protect your crown jewels from threat actors.
• Board members are now paying attention, and want to know what their teams are doing about it, now. What can be done to answer this?

With hybrid and decentralized clinical trials becoming the new normal, the use of sensor-based wearables, monitoring devices and clinical trial apps intended to regularly collect PRO and experience data are critically important to the success of the trial.  Choosing, testing, modifying, and then validating devices and solutions for trials can be complex, yet it needs to be done quickly and effectively. The answers and validation are often, "outside the building" with the patients, caregivers, and investigators who will use these devices and tools. This will be a highly engaging conversation about the real-world concerns and factors about preparing for success. 

Join Todd Greenwood PH.D, Director of Client Solutions, Medullan, Vasundhara Sridharan, Principle user experience researcher, Medullan and Adriano Garcez, Director, Digital Health Strategy & Implementation, Medullan as they discuss:

• Standardize and accelerate the process of choosing clinical trial devices
• Ensure that devices provide endpoints that are both fit-for-purpose and exploratory
• Improve the consistency of wearables and devices used across the clinical research program
• Develop repeatable processes for future device selection

Join Matthew McCarty, Integrated Customer Solutions, ERT, Elisa Cascade, EVP, eCOA, ERT and Matt Johnson, Vice President, Wearables & Digital Biomarkers, ERT as they discuss the key learning objectives:

• Understand current environment and implications of moving towards a decentralized trial framework
• Understand the difference in Stakeholder perspective and addressing practical needs across the start-up, conduct, and close-out phases of trial operations
• Understand the opportunity for trial enhancement by leveraging connected devices and digital endpoints capture into trials
•  Understand considerations for data capture, analysis and clinical workflow in a decentralized model, including trial oversight implications